Clinical trials: Brain Tumor, Pediatric
Pediatric Brain Stem Glioma
Prospective Trial of Two Hypofractionated Radiotherapy Regimens Versus Conventional Radiotherapy in Diffuse Brainstem Glioma in Children
This Trial offers a reduction in patient burden, which is especially preferable in children with a poor compliance and poor performance status.
- Trial name
- NCT01878266
- Testing
- Hypofractionated Arm (1), Hypofractionated Arm (2), Conventional Arm (3)
- Where
- Egypt
- Volunteers
- 119 people
- Sponsor
- Children's Cancer Hospital Egypt 57357
Headache, Urinary Incontinence
Pediatric Patient Experience on a Diagnostic Path
The trial will determine the impact of an information- and education-focused interventions on the anxiety levels, and patients' experiences as well as satisfaction of patients aged 10-14 and their caregivers during the MR…
- Conditions
- Headache, Urinary Incontinence, Growth Deficiency, Visual Impairment
- Trial name
- NCT05199363
- Testing
- Information leaflet, Educational movie, Demonstration
- Where
- Poland
- Volunteers
- 300 people
- Sponsor
- Children's Memorial Health Institute, Poland
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Diffuse Intrinsic Pontine Glioma, Glioma, Malignant
ONC201 in Pediatric H3 K27M Gliomas
This was a Phase 1, open label, multicenter, 8-arm, dose escalation study of dordaviprone (ONC201) in pediatric patients with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and recurrent/refractory H3 K27M-mutant…
- Trial name
- NCT03416530
- Testing
- Dordaviprone (ONC201)
- Where
- 8 sites in United States
- Volunteers
- 134 people
- Sponsor
- Jazz Pharmaceuticals
Pediatric Solid Tumor, Pediatric Lymphoma
Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas
The study evaluates CLR 131 in children, adolescents, and young adults with relapsed or refractory malignant solid tumors and lymphoma and recurrent or refractory malignant brain tumors for which there are no standard treatment…
- Conditions
- Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG
- Trial name
- CLOVER-2 (NCT03478462)
- Testing
- CLR 131
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 30 people
- Sponsor
- Cellectar Biosciences, Inc.
Brain Tumors and/or Solid Tumors Including, Brain Stem Glioma
Methionine PET/CT Studies In Patients With Cancer
The purpose of this study is to test the usefulness of imaging with radiolabeled methionine in the evaluation of children and young adults with tumor(s). Methionine is a naturally occurring essential amino acid.
- Conditions
- Brain Tumors and/or Solid Tumors Including, Brain Stem Glioma, High Grade CNS Tumors, Ependymoma
- Trial name
- NCT00840047
- Testing
- Methionine
- Where
- United States
- Volunteers
- 503 people
- Sponsor
- St. Jude Children's Research Hospital
Central Nervous System Tumor, Pediatric
Genetic Study of Brain Tumors in Young Children
RATIONALE: Genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. PURPOSE: Genetic study to understand how genes may be involved in the development of brain tumors in…
- Trial name
- NCT00010101
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain Tumor, Primary
Radiation Induced Alterations in Resting State Brain Networks in Pediatric Brain Tumor Patients
With modern therapy, the survival rate for pediatric brain tumor patients has significantly improved, with over 70% of patients surviving their disease.
- Trial name
- NCT06185686
- Testing
- Cognitive testing, Resting State MRI/Precision functional mapping
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Drug-resistant Focal Epilepsies in Pediatric Population
Genetic and Electrophysiologic Study in Focal Drug-resistant Epilepsies
Brain somatic mutations are increasingly recognized as a major cause of focal epilepsies. These include mTOR pathway mutations underlying cortical malformations such as focal cortical dysplasia and hemimegalencephaly, and SLC35A2…
- Trial name
- GENEPHY (NCT02890641)
- Testing
- Sampling of blood, frozen resected tissues, and cerebrospinal fluid (CSF)
- Where
- France
- Volunteers
- 450 people
- Sponsor
- Fondation Ophtalmologique Adolphe de Rothschild
Brain and Central Nervous System Tumors
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002753
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Childhood Cancer, Childhood Solid Tumor
PRecISion Medicine for Children With Cancer
This is a multicentre prospective study of the feasibility and clinical value of a diagnostic service for identifying therapeutic targets and recommending personalised treatment for children and adolescents with high-risk cancer.
- Conditions
- Childhood Cancer, Childhood Solid Tumor, Childhood Brain Tumor, Childhood Leukemia
- Trial name
- PRISM (NCT03336931)
- Testing
- Molecular profiling and drug testing
- Where
- 8 sites in Australia
- Volunteers
- 550 people
- Sponsor
- Sydney Children's Hospitals Network
Brain and Central Nervous System Tumors, Pediatric Germ Cell Tumor
Cisplatin and Etoposide Prior to Radiation Therapy in Treating Patients With CNS Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Pediatric Germ Cell Tumor, Extragonadal Germ Cell Tumor
- Trial name
- NCT00002472
- Testing
- cisplatin, etoposide, conventional surgery
- Where
- 3 sites in United States
- Sponsor
- Mayo Clinic
Brain Tumor, Kidney Tumor
Engineering Immune Organoids to Study Pediatric Cancer
To engineer immune organoids from pediatric patient tissues using induced-pluripotent stem cells (iPSC)
- Conditions
- Brain Tumor, Kidney Tumor, Neuroblastoma, Sarcoma
- Trial name
- IMMUNEORGANOID (NCT05890781)
- Testing
- Skin biopsy, Fresh tumor sample, Blood sample
- Where
- 2 sites in France
- Volunteers
- 108 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Brain Tumor
High-dose Chemotherapy With Autologous Stem Cell Rescue in Pediatric High-risk Brain Tumors
Study No.: KSPNO-S-081 Reduced-dose Craniospinal Radiotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Rescue in Children with Newly Diagnosed High-risk Brain Tumor Study No.: KSPNO-S-082 High-dose Chemotherapy…
- Trial name
- NCT00798811
- Testing
- high-dose chemotherapy and autologous stem cell rescue
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Samsung Medical Center
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03330197
- Testing
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alaunos Therapeutics
Cognitive Impairment, Cognitive Decline
Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy
Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric…
- Conditions
- Cognitive Impairment, Cognitive Decline, Radiotherapy Side Effect, Radiotherapy; Complications
- Trial name
- LiBRA (NCT06051240)
- Testing
- Lithium
- Where
- 2 sites in Sweden
- Volunteers
- 84 people
- Sponsor
- Region Stockholm
Brain Tumor
Phenylbutyrate to Treat Children With Progressive or Recurrent Brain Tumors
This study will examine the safety and effectiveness of treating brain tumors in children with a continuous infusion of phenylbutyrate.
- Trial name
- NCT00006450
- Testing
- Phenylbutyrate
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute (NCI)
Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma
A Combined Study in Pediatric Cancer Patients for Dose Ranging and Efficacy/Safety of Plerixafor Plus Standard Regimens for Mobilization Versus Standard Regimens Alone
This is a multi-site study with plerixafor in pediatric cancer patients. The study will be conducted in 2 stages: Stage 1 is a dose-escalation study.
- Conditions
- Ewing's Sarcoma/Soft Tissue Sarcoma, Neuroblastoma, Brain Tumors
- Trial name
- NCT01288573
- Testing
- plerixafor
- Where
- 27 sites in Belgium, Czechia and 10 more
- Volunteers
- 46 people
- Sponsor
- Genzyme, a Sanofi Company
Pediatric Brain Tumor
Non-Helium Magnetoencephalography in Pediatric Brain Tumors
This observational study aims to evaluate the effectiveness of magnetoencephalography (MEG) in the preoperative assessment of pediatric brain tumors, particularly in determining the extent of resection, and compare it with…
- Trial name
- NCT06943742
- Testing
- Magnetoencephalography plus Computed Tomography/Magnetic Resonance Imaging
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Guangzhou Women and Children's Medical Center
Refractory Cancer, Refractory Neoplasm
9-ING-41 in Pediatric Patients With Refractory Malignancies.
9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.
- Conditions
- Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor
- Trial name
- NCT04239092
- Testing
- 9-ING-41, Irinotecan, Temozolomide
- Where
- 9 sites in United States
- Volunteers
- 40 people
- Sponsor
- Actuate Therapeutics Inc.